| Radiomics in glioblastoma: current status and challenges facing clinical implementation A Chaddad, MJ Kucharczyk, P Daniel, S Sabri, BJ Jean-Claude, T Niazi, ... Frontiers in oncology 9, 374, 2019 | 175 | 2019 |
| Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity DV Brown, G Filiz, PM Daniel, F Hollande, S Dworkin, S Amiridis, ... PLoS One 12 (2), e0172791, 2017 | 160 | 2017 |
| Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities P Daniel, S Sabri, A Chaddad, B Meehan, B Jean-Claude, J Rak, ... Frontiers in oncology 9, 41, 2019 | 154 | 2019 |
| Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization D Garnier, B Meehan, T Kislinger, P Daniel, A Sinha, B Abdulkarim, ... Neuro-oncology 20 (2), 236-248, 2018 | 124 | 2018 |
| Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme DV Brown, PM Daniel, MD Giovanna, A Gogos, W Ng, AP Morokoff, ... Oncotarget 6 (8), 6267, 2015 | 111 | 2015 |
| Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation P Daniel, G Filiz, DV Brown, F Hollande, M Gonzales, G D’Abaco, ... Oncogenesis 3 (6), e108-e108, 2014 | 104 | 2014 |
| Novel radiomic features based on joint intensity matrices for predicting glioblastoma patient survival time A Chaddad, P Daniel, C Desrosiers, M Toews, B Abdulkarim IEEE journal of biomedical and health informatics 23 (2), 795-804, 2018 | 76 | 2018 |
| Radiomics evaluation of histological heterogeneity using multiscale textures derived from 3D wavelet transformation of multispectral images A Chaddad, P Daniel, T Niazi Frontiers in oncology 8, 96, 2018 | 57 | 2018 |
| Integration of radiomic and multi-omic analyses predicts survival of newly diagnosed IDH1 wild-type glioblastoma A Chaddad, P Daniel, S Sabri, C Desrosiers, B Abdulkarim Cancers 11 (8), 1148, 2019 | 53 | 2019 |
| Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling PM Daniel, G Filiz, T Mantamadiotis Cell Death & Disease 7 (12), e2494-e2494, 2016 | 42 | 2016 |
| Mechanisms and antitumor activity of a binary EGFR/DNA–targeting strategy overcomes resistance of glioblastoma stem cells to temozolomide Z Sharifi, B Abdulkarim, B Meehan, J Rak, P Daniel, J Schmitt, N Lauzon, ... Clinical Cancer Research 25 (24), 7594-7608, 2019 | 34 | 2019 |
| Intratumor MAPK and PI3K signaling pathway heterogeneity in glioblastoma tissue correlates with CREB signaling and distinct target gene signatures PM Daniel, G Filiz, MJ Tymms, RG Ramsay, AH Kaye, SS Stylli, ... Experimental and molecular pathology 105 (1), 23-31, 2018 | 31 | 2018 |
| PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein PM Daniel, G Filiz, DV Brown, M Christie, PM Waring, Y Zhang, ... Neuro-oncology 20 (10), 1344-1355, 2018 | 30 | 2018 |
| Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities CX Sun, P Daniel, G Bradshaw, H Shi, M Loi, N Chew, S Parackal, V Tsui, ... Cancer Cell 41 (4), 660-677. e7, 2023 | 29 | 2023 |
| Deep radiomic signature with immune cell markers predicts the survival of glioma patients A Chaddad, P Daniel, M Zhang, S Rathore, P Sargos, C Desrosiers, ... Neurocomputing 469, 366-375, 2022 | 23 | 2022 |
| Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma P Daniel, B Meehan, S Sabri, F Jamali, JN Sarkaria, D Choi, D Garnier, ... Neuro-Oncology Advances 4 (1), vdac076, 2022 | 16 | 2022 |
| Radiomics in glioblastoma: current status and challenges facing clinical implementation. Front Oncol. 2019; 9: 374 A Chaddad, MJ Kucharczyk, P Daniel, S Sabri, BJ Jean-Claude, T Niazi, ... | 13 | 2019 |
| PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma RJ Duchatel, ER Jackson, SG Parackal, D Kiltschewskij, IJ Findlay, ... The Journal of clinical investigation 134 (6), 2024 | 12 | 2024 |
| Investigating neural stem cell and glioma stem cell self-renewal potential using extreme limiting dilution analysis (ELDA) HPT Nguyen, PM Daniel, G Filiz, T Mantamadiotis Bio-protocol 8 (17), e2991-e2991, 2018 | 12 | 2018 |
| Pediatric glioma histone H3. 3 K27M/G34R mutations drive abnormalities in PML nuclear bodies HPJ Voon, L Hii, A Garvie, M Udugama, B Krug, C Russo, AC Chüeh, ... Genome Biology 24 (1), 284, 2023 | 11 | 2023 |
